| |
| We are proud to announce that we've been nominated for the 11th Annual Vaccine Industry Excellence Awards in the Best Contract Research Organization Award category. We have recently developed a fully (c)GMP compliant, non-haemagglutinating, wild-type strain of Influenza A H3N2 (A/Belgium/4217/2015) for use in human challenge trials. |
| |
| This unique challenge agent is being employed within the SGS human challenge unit in healthy volunteer studies and, owing to its high attack rate and consistently broad shedding profile, is capable of providing early evidence regarding VE, to more rapidly enable candidate selection prior to vaccination programs. A/Belgium may also facilitate research into markers of contagion and allow for timely interventions to reduce future disease burden. |
| |
| To support our continuous Vaccine R&D effort, thank you for your vote for SGS as “The Best Contract Research Organization": |
| |
 |
| |
| Contact us: clinicalresearch@sgs.com |
| |
Read more about SGS Infectious Diseases services: www.sgs.com/infectiousdisease
and join the Scientific Community – Connect on LinkedIn: www.sgs.com/LinkedIn-Life |
| |
